Brian Drachman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian Drachman has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Pablo Garcia-Pavia
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Manuel de Falla, 2, Madrid 28222
4 shared publications Chafic Karam
University of Pennsylvania
2 shared publicationsFelipe Simoes Jones
Department of Neurology, University of Pennsylvania
2 shared publications- Franca Angeli
Departments of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
2 shared publications Janice Pieretti
University of Pennsylvania
2 shared publications- Marianna Fontana
University College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e012112
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis
The demographics of patients with transthyretin amyloidosis with cardiomyopathy have evolved over the past decade, mostly driven by improved awareness of the disease among clinicians, noninvasive imaging tools for diagnosis, and new, effective treatments. Patients are now diagnosed earlier in their disease course, and treatment is initiated in those with milder disease, leading to improved outcomes. Earlier treatment of patients with milder disease may lead to accelerated disease stabilization and greater preservation of function. In addition, identification of patients with transthyretin amyloidosis with cardiomyopathy at an earlier disease stage translates to healthier study populations at enrollment in clinical trials, with slower disease progression compared with patients in prior trials. In this context, effect sizes between active treatment and placebo arms will likely be smaller than those seen in historic trials, although it is still possible to observe clinically relevant differences. In this review, we discuss how patient characteristics have changed from the ATTR-ACT trial to the more recent APOLLO-B, ATTRibute-CM, and HELIOS-B studies. In addition, we consider how measures of the minimal clinically important difference for particular end points can assist in clinical decision-making and targeting treatment goals. Treatment goals are evolving over time with the need for evidence-based recommendations in this clinical space. Lastly, we address unmet needs and future expectations for the management of transthyretin amyloidosis with cardiomyopathy.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e012112
Open AccessChanging Treatment Landscape in Transthyretin Cardiac Amyloidosis
The demographics of patients with transthyretin amyloidosis with cardiomyopathy have evolved over the past decade, mostly driven by improved awareness of the disease among clinicians, noninvasive imaging tools for diagnosis, and new, effective treatments. Patients are now diagnosed earlier in their disease course, and treatment is initiated in those with milder disease, leading to improved outcomes. Earlier treatment of patients with milder disease may lead to accelerated disease stabilization and greater preservation of function. In addition, identification of patients with transthyretin amyloidosis with cardiomyopathy at an earlier disease stage translates to healthier study populations at enrollment in clinical trials, with slower disease progression compared with patients in prior trials. In this context, effect sizes between active treatment and placebo arms will likely be smaller than those seen in historic trials, although it is still possible to observe clinically relevant differences. In this review, we discuss how patient characteristics have changed from the ATTR-ACT trial to the more recent APOLLO-B, ATTRibute-CM, and HELIOS-B studies. In addition, we consider how measures of the minimal clinically important difference for particular end points can assist in clinical decision-making and targeting treatment goals. Treatment goals are evolving over time with the need for evidence-based recommendations in this clinical space. Lastly, we address unmet needs and future expectations for the management of transthyretin amyloidosis with cardiomyopathy.
- Open Access
- 29 October 2024
- Published by Taylor & Francis in Amyloid
- Vol. 32 (1) , 14-21
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study
The investigational monoclonal antibody PRX004 is designed to specifically target and deplete TTR amyloid. Here, we report on the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of PRX004 in patients with ATTRv amyloidosis. This global, multicentre, phase 1 trial comprised a 3 + 3 dose-escalation phase and a long-term extension (LTE) phase (NCT03336580). In the dose-escalation phase, patients received PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months. In the LTE, eligible patients could receive up to 15 additional doses. Patients who received doses of ≥3 mg/kg for ≥9 months were assessed for Global Longitudinal Strain (GLS) and Neuropathy Impairment Score (NIS). The primary objective was to determine the maximum tolerated dose (MTD) of PRX004. Overall, 21 patients with ATTRv amyloidosis completed the dose-escalation phase; 17 subsequently enrolled in the LTE. The MTD was not reached. PRX004 was well tolerated at all doses, with dose-proportional exposure. GLS and NIS were improved or maintained over 9 months (n = 7). PRX004 was well tolerated in patients with ATTRv amyloidosis and demonstrated potential clinical activity. A phase 2 randomised controlled trial in ATTR cardiomyopathy is ongoing (NCT05442047).
- 29 October 2024
- Published by Taylor & Francis in Amyloid
- Vol. 32 (1) , 14-21
Open AccessPRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study
The investigational monoclonal antibody PRX004 is designed to specifically target and deplete TTR amyloid. Here, we report on the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of PRX004 in patients with ATTRv amyloidosis. This global, multicentre, phase 1 trial comprised a 3 + 3 dose-escalation phase and a long-term extension (LTE) phase (NCT03336580). In the dose-escalation phase, patients received PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months. In the LTE, eligible patients could receive up to 15 additional doses. Patients who received doses of ≥3 mg/kg for ≥9 months were assessed for Global Longitudinal Strain (GLS) and Neuropathy Impairment Score (NIS). The primary objective was to determine the maximum tolerated dose (MTD) of PRX004. Overall, 21 patients with ATTRv amyloidosis completed the dose-escalation phase; 17 subsequently enrolled in the LTE. The MTD was not reached. PRX004 was well tolerated at all doses, with dose-proportional exposure. GLS and NIS were improved or maintained over 9 months (n = 7). PRX004 was well tolerated in patients with ATTRv amyloidosis and demonstrated potential clinical activity. A phase 2 randomised controlled trial in ATTR cardiomyopathy is ongoing (NCT05442047).
- 10 May 2024
- Published by Morressier GmbH
Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction PC95 (#17)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction PC95 (#17)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Treatment characteristics in a cohort of patients with hereditary transthyretin amyloidosis (S7.010)
Objective: We aimed to describe and compare treatment modalities in a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the University of Pennsylvania Amyloidosis Center. Background: Treatments for hATTR amyloidosis fall into 2 major categories: transthyretin (TTR) stabilizers (tafamidis and diflunisal) and TTR gene silencers(patisiran and inotersen). Most patients are on one or the other. However, some patients are on both classes of treatment (combination therapy) and there is lack of data to determine whether combination therapy is superior to monotherapy. Design/Methods: We performed a retrospective chart review of hATTR patients seen at the University of Pennsylvania between 2018 and 2022. Patient characteristics, treatment, and outcomes were collected and a comparison will be made between the different groups of patients based on treatment modalities. Results: 164 patients with hATTR were identified. The most common gene mutations were V122I (87 patients, 53%) and T60A (32 patients, 20%) and V30M (17 patients, 10%). 122 (74%) patients were symptomatic. 47 symptomatic patients (39%) had only cardiac symptoms, 15 patients (12%) had only neurological symptoms, and 60 patients (49%) had a mixed phenotype. 104 (85%) of the symptomatic received treatment, of which 36 (35%) patients received combination therapy with both a gene silencer and protein stabilizer, and 68 (65%) patients received treatment with only one of these medication classes. Statistical analysis comparing cardiac biomarkers and Neuropathy Impairment Scores between patients receiving combination versus monotherapy based on will be performed and presented during the AAN 2023 meeting. Conclusions: A significant number of hATTR patients are on both gene silencing and protein stabilizing therapy. There is a lack of data regarding whether patients on combination therapy differ in disease severity compared to those on monotherapy. This study will help bridge this knowledge gap by comparing disease severity and progression between the two groups. Disclosure: Dr. Qarni has nothing to disclose. Mr. Sarmiento Bustamante has nothing to disclose. Dr. Simoes Jones has nothing to disclose. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylum. Dr. Khella has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Pieretti has nothing to disclose. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Treatment characteristics in a cohort of patients with hereditary transthyretin amyloidosis (S7.010)
Objective: We aimed to describe and compare treatment modalities in a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the University of Pennsylvania Amyloidosis Center. Background: Treatments for hATTR amyloidosis fall into 2 major categories: transthyretin (TTR) stabilizers (tafamidis and diflunisal) and TTR gene silencers(patisiran and inotersen). Most patients are on one or the other. However, some patients are on both classes of treatment (combination therapy) and there is lack of data to determine whether combination therapy is superior to monotherapy. Design/Methods: We performed a retrospective chart review of hATTR patients seen at the University of Pennsylvania between 2018 and 2022. Patient characteristics, treatment, and outcomes were collected and a comparison will be made between the different groups of patients based on treatment modalities. Results: 164 patients with hATTR were identified. The most common gene mutations were V122I (87 patients, 53%) and T60A (32 patients, 20%) and V30M (17 patients, 10%). 122 (74%) patients were symptomatic. 47 symptomatic patients (39%) had only cardiac symptoms, 15 patients (12%) had only neurological symptoms, and 60 patients (49%) had a mixed phenotype. 104 (85%) of the symptomatic received treatment, of which 36 (35%) patients received combination therapy with both a gene silencer and protein stabilizer, and 68 (65%) patients received treatment with only one of these medication classes. Statistical analysis comparing cardiac biomarkers and Neuropathy Impairment Scores between patients receiving combination versus monotherapy based on will be performed and presented during the AAN 2023 meeting. Conclusions: A significant number of hATTR patients are on both gene silencing and protein stabilizing therapy. There is a lack of data regarding whether patients on combination therapy differ in disease severity compared to those on monotherapy. This study will help bridge this knowledge gap by comparing disease severity and progression between the two groups. Disclosure: Dr. Qarni has nothing to disclose. Mr. Sarmiento Bustamante has nothing to disclose. Dr. Simoes Jones has nothing to disclose. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylum. Dr. Khella has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Pieretti has nothing to disclose. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Characteristics of a single-center cohort of patients with hereditary transthyretin amyloidosis (P13-8.015)
Objective: To describe patients’ characteristics of a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the Penn Amyloidosis Center between 2018 and 2022. Background: The characteristics of hATTR patients and their prognosis varies greatly depending on the type of TTR mutation and whether the patient lives in an endemic area versus a non-endemic area. There is a need for referring physicians to better understand characteristics of hATTR patients in the US. Design/Methods: We performed a retrospective chart review of all patients seen at the University of Pennsylvania between 2018 and 2022 with confirmed hATTR. Data was collected on patient demographics, TTR gene mutations, and symptomatology. Results: 164 patients with hATTR were identified. 98 patients (60%) were male, and 66 (40%) were female. The most common gene mutations were V122I (87 patients, 53%), T60A (32 patients, 20%), and V30M (17 patients, 10%), and Phe64 (12 patients, 7%). 122 (74%) patients were symptomatic. The average age for these patients at symptom onset was 64 years; average age at diagnosis was 67 years. 22 patients (13%) were deceased at the time of chart review, on average 20 months after diagnosis and 45 months after symptom onset. 47 symptomatic patients (39%) had only cardiac symptoms such as congestive heart failure, 15 patients (12%) had only neurological symptoms such as neuropathy, and 60 patients (49%) had both cardiac and neurological symptoms. 20 symptomatic patients (16%) had concurrent diabetes, and 54 patients (44%) had a history of carpal tunnel syndrome. Conclusions: This study summarizes characteristics of a large patient cohort at an urban academic referral center. These findings can help physicians taking care of hATTR patients discuss disease behavior and prognosis in their patient population. Overall, a trend in shorter diagnosis delay was observed in our study showing the possibility of increase awareness about hATTR among referring physicians. Disclosure: Mr. Sarmiento Bustamante has nothing to disclose. Dr. Qarni has nothing to disclose. Dr. Simoes Jones has nothing to disclose. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylum. Dr. Khella has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Pieretti has nothing to disclose. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Characteristics of a single-center cohort of patients with hereditary transthyretin amyloidosis (P13-8.015)
Objective: To describe patients’ characteristics of a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the Penn Amyloidosis Center between 2018 and 2022. Background: The characteristics of hATTR patients and their prognosis varies greatly depending on the type of TTR mutation and whether the patient lives in an endemic area versus a non-endemic area. There is a need for referring physicians to better understand characteristics of hATTR patients in the US. Design/Methods: We performed a retrospective chart review of all patients seen at the University of Pennsylvania between 2018 and 2022 with confirmed hATTR. Data was collected on patient demographics, TTR gene mutations, and symptomatology. Results: 164 patients with hATTR were identified. 98 patients (60%) were male, and 66 (40%) were female. The most common gene mutations were V122I (87 patients, 53%), T60A (32 patients, 20%), and V30M (17 patients, 10%), and Phe64 (12 patients, 7%). 122 (74%) patients were symptomatic. The average age for these patients at symptom onset was 64 years; average age at diagnosis was 67 years. 22 patients (13%) were deceased at the time of chart review, on average 20 months after diagnosis and 45 months after symptom onset. 47 symptomatic patients (39%) had only cardiac symptoms such as congestive heart failure, 15 patients (12%) had only neurological symptoms such as neuropathy, and 60 patients (49%) had both cardiac and neurological symptoms. 20 symptomatic patients (16%) had concurrent diabetes, and 54 patients (44%) had a history of carpal tunnel syndrome. Conclusions: This study summarizes characteristics of a large patient cohort at an urban academic referral center. These findings can help physicians taking care of hATTR patients discuss disease behavior and prognosis in their patient population. Overall, a trend in shorter diagnosis delay was observed in our study showing the possibility of increase awareness about hATTR among referring physicians. Disclosure: Mr. Sarmiento Bustamante has nothing to disclose. Dr. Qarni has nothing to disclose. Dr. Simoes Jones has nothing to disclose. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Khella has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylum. Dr. Khella has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Brian Drachman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Pieretti has nothing to disclose. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alnylam. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
- Top Cited PapersOpen Access
- 1 January 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (1) , e008193
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Methods: Patients with transthyretin amyloid cardiomyopathy who completed ATTR-ACT could enroll in an LTE, continuing with the same tafamidis dose or, if previously treated with placebo, randomized (2:1) to tafamidis meglumine 80 or 20 mg. All patients in the LTE transitioned to tafamidis free acid 61 mg (bioequivalent to tafamidis meglumine 80 mg) following a protocol amendment. In this interim analysis, all-cause mortality was assessed in patients treated with tafamidis meglumine 80 mg in ATTR-ACT continuing in the LTE, compared with those receiving placebo in ATTR-ACT transitioning to tafamidis in the LTE. Results: Median follow-up was 58.5 months in the continuous tafamidis group (n=176) and 57.1 months in the placebo to tafamidis group (n=177). There were 79 (44.9%) deaths with continuous tafamidis and 111 (62.7%) with placebo to tafamidis (hazard ratio, 0.59 [95% CI, 0.44–0.79]; P P =0.05) and wild-type transthyretin amyloidosis (0.61 [0.43–0.87]; P =0.006); and baseline New York Heart Association class I and II (0.56 [0.38–0.82]; P =0.003) and class III (0.65 [0.41–1.01]; P =0.06). Conclusions: In the LTE, patients initially treated with tafamidis in ATTR-ACT had substantially better survival than those first treated with placebo, highlighting the importance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01994889 and NCT02791230.
- 1 January 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (1) , e008193
Top Cited PapersOpen AccessLong-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Methods: Patients with transthyretin amyloid cardiomyopathy who completed ATTR-ACT could enroll in an LTE, continuing with the same tafamidis dose or, if previously treated with placebo, randomized (2:1) to tafamidis meglumine 80 or 20 mg. All patients in the LTE transitioned to tafamidis free acid 61 mg (bioequivalent to tafamidis meglumine 80 mg) following a protocol amendment. In this interim analysis, all-cause mortality was assessed in patients treated with tafamidis meglumine 80 mg in ATTR-ACT continuing in the LTE, compared with those receiving placebo in ATTR-ACT transitioning to tafamidis in the LTE. Results: Median follow-up was 58.5 months in the continuous tafamidis group (n=176) and 57.1 months in the placebo to tafamidis group (n=177). There were 79 (44.9%) deaths with continuous tafamidis and 111 (62.7%) with placebo to tafamidis (hazard ratio, 0.59 [95% CI, 0.44–0.79]; P P =0.05) and wild-type transthyretin amyloidosis (0.61 [0.43–0.87]; P =0.006); and baseline New York Heart Association class I and II (0.56 [0.38–0.82]; P =0.003) and class III (0.65 [0.41–1.01]; P =0.06). Conclusions: In the LTE, patients initially treated with tafamidis in ATTR-ACT had substantially better survival than those first treated with placebo, highlighting the importance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01994889 and NCT02791230.